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At the end of 2017, approximately 36.9 million peo­
ple were living with HIV infection, with 1.8 million 
becoming newly infected during that year1. The WHO 
recommends that all people with HIV infection receive 
antiretroviral therapy (ART) (Table 1). ART has trans­
formed HIV infection into a chronic disease. As a con­
sequence, by the year 2030, a modelling study suggests 
that 73% of people with HIV infection will be aged 
≥50 years and 78% of individuals living with HIV 
infection will have cardiovascular disease (CVD)2. 
As shown in Fig. 1, individuals infected with HIV have 
been shown to be at an increased risk of CVD, includ­
ing sudden cardiac death3, acute myocardial infarction 
(MI)4, stroke5, peripheral artery disease and heart fail­
ure with either reduced or preserved ejection fraction6. 
This Review focuses on coronary heart disease in the 
setting of HIV infection.
Although ART controls the HIV infection, the dis­
ease is not cured; individuals must continue taking ART 
indefinitely, and, in this setting, chronic inflammation 
and immune activation persist, leading to downstream 
consequences including the development of athero­
sclerotic CVD (ASCVD)7. The population living with 
HIV is ageing, and, although traditional CVD risk factors 
are crucial contributors to CVD, HIV­ specific factors, 
including ART, chronic inflammation and immune acti­
vation, have a role in HIV­ associated CVD, including 
atherosclerosis. The atherosclerosis associated with 
HIV infection differs in important ways from athero­
sclerosis in the non­ HIV setting in terms of both aetio­
logical factors and clinical presentation. The low­ grade 
inflammation associated with HIV infection accele­
rates atherogenesis through a variety of mechanisms. 
For example, atherosclerotic plaques in patients with 
HIV infection are more likely to be non­ calcified and 
more prone to rupture than atherosclerotic plaques in 
patients without HIV infection8,9. Around one­ half of 
MI events among patients with HIV infection are related 
to an imbalance in cardiac oxygen demand and supply 
rather than to atherothrombotic disease10. Finally, indi­
viduals infected with HIV who develop acute coronary 
syndrome (ACS) are, on average, a decade younger 
than uninfected patients with ACS and are more likely 
to be men who smoke and have low levels of HDL 
cholesterol (HDL­ C)11.
In this Review, we address the epidemiology and clin­
ical features of CVD in people living with HIV infec­
tion and discuss the mechanisms of HIV­ associated 
ASCVD and the management of CVD risk factors in 
people with HIV infection. Although much of this infor­
mation is similar to that in people with CVD without 
HIV infection, important differences exist, particularly 
on the potential future therapies for CVD in people 
living with HIV.
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Epidemiology of CVD in HIV infection
Before the advent of ART in the late 1990s, HIV infection 
almost always progressed to AIDS, with frequent oppor­
tunistic infections leading to death. Cardiomyopathy 
with systolic dysfunction was common in patients with 
AIDS and was associated with high short­ term mortal­
ity (Table 2). For example, in one small study from the 
pre­ ART era, median survival was 101 days in patients 
with AIDS with dilated cardiomyopathy compared with 
472 days in patients with AIDS with normal ven­
tricular function12. Cardiomyopathy was attributed to 
direct HIV infection of the myocardium with or with­
out myocarditis, co­ infection with other viruses such 
as coxsackievirus B3 and Cytomegalovirus (CMV), 
opportunistic infections and nutritional disorders13. 
Pericardial effusions were also common and presaged a 
high short­term mortality14.
The incidence of HIV­ associated cardiomyopathy has 
decreased from the pre­ ART era, from 25.6 to 3.9 cases 
per 1,000 person­ years15. The phenotype of cardio­
myopathy has also changed markedly, from symptomatic 
systolic dysfunction with left ventricular dilatation in the 
pre­ ART era to asymptomatic systolic or diastolic dys­
function detected by echocardiography in ART­ treated 
patients with HIV infection. Whereas older ARTs, such 
as nucleoside reverse­ transcriptase inhibitors (NRTIs), 
were implicated in mitochondrial toxicity leading to 
dilated cardiomyopathy16, more recent studies have sug­
gested that protease inhibitor use is related to increased 
cardiovascular mortality and 30­day re­ admission for 
heart failure17.
A 2018 systematic review of 80 longitudinal studies 
of CVD in HIV cohorts, which included 793,635 indi­
viduals living with HIV, concluded that the risk of MI 
and stroke in patients with HIV infection was increased 
by 2.16 (95% CI 1.68–2.77) compared with unin­
fected individuals18. The magnitude of this increased 
risk is similar to that associated with major CVD risk 
factors, such as diabetes mellitus and hypertension19. 
Given that the prevalence of HIV infection is much 
lower than the prevalence of these traditional CVD risk 
factors, the overall influence of HIV infection on the 
risk of CVD would, at first glance, seem to be low; how­
ever, the global burden of HIV­ associated MI and stroke 
has tripled over the past two decades and now accounts 
for 2.6 disability­adjusted life­ years on an annual basis18.
The burden of traditional CVD risk factors is high 
in people with HIV infection. A study published in 
2015 on the large VACS VC cohort showed that <2% 
of patients with HIV had optimal levels of traditional 
CVD risk factors20. However, the increased risk of MI 
in people with HIV infection persists after adjustment 
for these risk factors; in the same cohort, the increased 
risk of MI was approximately 50% after adjusting for 
Framingham risk factors, comorbidities and substance 
abuse4. The risk of MI was higher in those with higher 
HIV­1 RNA levels in blood (≥500 copies per ml) and 
lower CD4+ T cell counts (<200 cells per µl), but the risk 
was still elevated in those with low HIV­1 RNA levels 
and high CD4+ T cell counts4. Although most of the 
study participants were men, the risk of MI was also 
significantly increased in women with HIV infection21.
As with MI, the risk of stroke is also increased in 
people with HIV infection18. Globally, the risk of stroke 
in patients with HIV infection is approximately double 
that in individuals without HIV infection18, but, in one 
study from the USA, the HR was 1.40 (95% CI 1.17–1.69), 
decreasing to 1.21 (95% CI 1.01–1.46) after adjustment 
for demographic and stroke risk factors5. A much higher 
risk of stroke has been reported in African patients with 
HIV, in whom initiation of ART is usually delayed after 
infection, with the highest risk of stroke being during 
the first 6 months after starting ART22. Risk factors for 
stroke in African patients with HIV infection compared 
with uninfected patients with stroke included younger 
age, large­ artery disease and a low CD4+ T cell count 
after initiation of ART23.
The relationship between use of ART and the risk of 
MI is not straightforward. Case reports of MI in individ­
uals with HIV infection began to appear soon after the 
introduction of ART24 (Table 2). Early protease inhibi­
tors were associated with the incidence of MI in a 2007 
report, in which each cumulative year of protease inhibi­
tor use was associated with a 10% increase in the risk of 
MI, even after adjusting for the changes in blood lipid 
levels caused by the protease inhibitor therapy25. Some of 
the newer protease inhibitors are likely to be safer. More 
recent reports indicate that among two widely used, 
recent­ generation protease inhibitors, atazanavir was 
not associated with an increased risk of CVD compared 
with darunavir26,27.
Abacavir, a widely prescribed NRTI, was reported 
in several observational cohorts to be associated with 
an increased risk of MI28–31, possibly because this 
drug increases vascular inflammation and platelet 
reactivity32. However, other studies, including an FDA 
meta­ analysis33, do not show an increased risk of MI 
with abacavir. Nevertheless, US guidelines recom­
mend that abacavir be avoided or used with caution in 
individuals at high risk of CVD34.
The START trial35 demonstrated unequivocally that 
starting ART in adults with HIV infection and a CD4+ 
T cell count of >500 cells per μl reduced mortality and 
serious AIDS­ related and non­ AIDS­related events 
Key points
•	As	improvements	to	antiretroviral	therapies	have	led	to	better	control	of	HIV	infection	
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CD4+ T cell counts
T cell subset that has a role in 
the immune system response 
against pathogens, infections 
and illnesses. a normal CD4+ 
T cell count is 500–1,500 cells 
per µl of plasma. CD4+ T cells 
are the main target cell of HiV, 
and the CD4+ T cell count is 
used to monitor the status of 
the HiV infection and the 
efficacy of the antiretroviral 
therapy.
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compared with starting ART therapy after the CD4+ 
T cell count had declined to 350 cells per μl. However, 
the incidence of cardiovascular events was low in this 
study, and, although a nonsignificant trend towards a 
reduction in the risk of cardiovascular events with early 
initiation of the treatment was observed, no definitive 
benefit was demonstrated. In substudies of the START 
trial, early initiation of ART did not improve arterial 
elasticity36 and led to increased total and LDL cholesterol 
(LDL­C) levels in plasma but also to increased HDL­C 
levels and lower use of antihypertensive medications 
compared with delayed ART initiation37. Therefore, 
the effect of early initiation of ART on the risk of CVD 
remains unknown.
Earlier initiation of ART and the use of safer forms of 
ART from a CVD risk perspective might have resulted 
in a decrease in the risk of MI over the past decade, but 
additional studies with longer­ term follow­ up will be 
needed to evaluate definitively the effect of early initia­
tion of ART on cardiovascular events. Some studies have 
reported a declining relative risk of MI in the setting of 
HIV infection38, which might be related to the use of 
newer protease inhibitors27, better control of HIV infec­
tion39 or modification of traditional CVD risk factors 
over time40, including smoking41. Thus far, no studies 
have reported on the effect of integrase inhibitors on 
cardiovascular events in HIV infection.
Clinical features of HIV- associated CVD
Early reports of coronary heart disease among individu­
als with HIV infection were remarkably consistent in the 
described clinical characteristics11,33,42–47. Patients with 
HIV infection and coronary heart disease in these stud­
ies were >90% men and had a mean age of 42–50 years, 
about a decade younger than patients with ACS with­
out HIV infection in the reports with control groups11. 
More than half were current smokers11,33,42–44,46,47, and, 
in studies including blood lipid measurements, plasma 
HDL­ C levels were lower in patients with coronary heart 
disease and HIV infection than in uninfected patients 
with coronary heart disease11,43. As would be expected in 
the population with HIV infection, single­ vessel disease 
Table 1 | Commonly used antiretroviral drugs
Class Mechanism of action179 generic name abbreviation Brand name year of Fda 
approval
Protease inhibitors Selectively bind to HIV proteases and inhibit cleavage of 
Gag- Pro-Pol polyproteins in HIV- infected cells, resulting in 
the production of immature, non- infectious virions
Atazanavir ATV Reyataz 2003
Darunavir DRV Prezista 2006
Fosamprenavir FOS- APV, FPV Lexiva 2003
Ritonavir RTV Norvir 1996
Saquinavir SQV Invirase 1995
Tipranavir TPV Aptivus 2005
Nucleoside reverse- 
transcriptase 
inhibitors
Inhibit viral replication through competitive binding to the 
HIV enzyme reverse transcriptase, leading to termination of 
DNA chain elongation
Abacavir ABC Ziagen 1998
Emtricitabine FTC Emtriva 2003
Lamivudine 3TC Epivir 1995
Tenofovir 
fumarate 
disoproxil
TDF Viread 2001
Zidovudine AZT Retrovir 1987
Non- nucleoside 
reverse- 
transcriptase 
inhibitors
Prevent HIV reverse transcriptase from adding new 
nucleotides to the DNA chain, leading to a decline in viral 
replication
Doravirine DOR Pifeltro 2018
Efavirenz EFV Sustiva 1998
Etravirine ETR Intelence 2008
Nevirapine NVP Viramune 1996
Rilpivirine RPV Edurant 2011
CCR5 antagonist Entry inhibitor ; binds to the cell membrane receptor CCR5, 
thereby blocking the entry of CCR5-tropic viruses into CD4+ 
T cells
Maraviroc MVC Selzentry 2007
Integrase inhibitors Prevent binding of the pre- integration complex to the 
host cell DNA , terminating the integration step of HIV 
replication
Dolutegravir DTG Tivicay 2013
Raltegravir RAL Isentress 2007
Fusion inhibitor Prevents viral fusion to CD4+ T cells by binding to the HIV 
envelope glycoprotein 41
Enfuvirtide T-20 Fuzeon 2003
Pharmacokinetic 
enhancer
Protease inhibitors combined with integrase inhibitors  
to improve potency of the antiviral agent and to decrease 
pill burden by increasing trough drug concentration, drug 
half- life and peak concentration (Cmax) in plasma
Cobicistat COBI Tybost 2014
Post- attachment 
inhibitor
Monoclonal antibody that binds to the CD4 molecule and 
blocks viral entry into the cell
Ibalizumab IBA Trogarzo 2018
CCR5, CC- chemokine receptor 5.
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was common11,43,46,47, and, in those with ACS, risk scores 
were lower than in individuals with ACS without HIV 
infection11. Therefore, as expected, in­ hospital mortality 
in patients with ACS and HIV infection was not high for 
that era: 4.8% (9 of 189 patients) in the studies in which 
this outcome was reported11,42,43,46,47.
Coronary angioplasty in these early studies was as 
effective in patients with HIV infection as in patients 
without HIV infection; however, restenosis was more 
common in the setting of HIV infection11,43. The wide­
spread use of coronary stents has reduced the incidence 
of restenosis, and drug­ eluting stents have been shown 
to reduce cardiovascular events in patients with or with­
out HIV infection48. Nevertheless, in a small study in 
which follow­ up coronary angiography was performed 
routinely in individuals with HIV infection undergoing 
coronary stenting, the incidence of restenosis with drug­ 
eluting stents was 19%49. Total CD8+ T cell count, but 
not CD4+ T cell count, was associated with restenosis, as 
was plasma C­ reactive protein (CRP) level at follow­ up 
(but not baseline)49. These results suggest that persistent 
inflammation in patients with HIV infection might be 
causally related to restenosis.
In a contemporary cohort of 226 patients with HIV 
infection who were followed up for 3 years after hospi­
talization for ACS, the risk of recurrent ACS was not 
increased compared with individuals without HIV 
infection (HR 1.08, 95% CI 0.76–1.54)50. HIV infection 
was significantly associated with all­ cause mortality, 
but this association was not present among individ­
uals with CD4+ T cell counts ≥500 cells per μl. These 
intermediate­ term results are encouraging; however, 
longer­ term follow­ up studies of patients with HIV 
infection and coronary heart disease are lacking.
Imaging studies have provided insight into the fea­
tures and pathophysiology of HIV­ associated coronary 
heart disease. Overall stenosis was less severe among 
men with ACS and HIV infection than in matched, 
uninfected individuals with ACS, although the num­
bers of diseased coronary vessels and lesions were sim­
ilar in both groups51. In another study, plaque burden 
assessed as lesion severity in intracoronary ultrasono­
graphy findings was also lower in patients with ACS 
and HIV infection than in patients with ACS without 
HIV infection52. Furthermore, hyperechoic, non­ calcified 
coronary plaques were much more common in patients 
with HIV (100% versus 35%; P < 0.05).
A higher prevalence of non­ calcified coronary lesions 
among patients with HIV than in individuals without 
HIV infection was also reported in a meta­ analysis of 
individuals without coronary symptoms who were eval­
uated with coronary CT9. In nine studies with 1,229 
patients infected with HIV and 1,029 controls with­
out HIV infection, the rates of non­ calcified coronary 
plaques were higher in the HIV group (58% versus 17%; 
OR 3.26, 95% CI 1.30–8.18). Some evidence suggests 
that these non­ calcified plaques are particularly amena­
ble to LDL­ C lowering with statin therapy. In a small 
clinical trial in which patients with HIV infection were 
randomly assigned to receive atorvastatin or placebo and 
followed up for 1 year, atorvastatin significantly reduced 
non­ calcified coronary plaque volume compared with 
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Fig. 1 | overview of changes in HiV treatment and HiV- associated cardiovascular diseases. The types of cardiovascular 
complications associated with HIV infection have changed in the pre- antiretroviral therapy (ART) and ART eras and are 
likely to continue evolving in the future as new medications and treatment approaches emerge. In the pre- ART era, dilated 
cardiomyopathy and pericardial effusions were the most commonly reported cardiovascular issues in patients infected 
with HIV14,176. After the introduction of protease inhibitors (PIs) in the late 1990s, atherosclerotic complications including 
myocardial infarction were described177,178. More recently , reports of heart failure and rhythm abnormalities are now 
emerging in the setting of HIV infection3,6. In the future, among individuals with access to ART, HIV infection will be a chronic 
disease state with increased risk of coronary artery disease19. CCR5, CC- chemokine receptor 5; NNRTI, non- nucleoside 
reverse- transcriptase inhibitor ; NRTI, nucleoside reverse- transcriptase inhibitor.
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placebo53. Why individuals infected with HIV have a 
higher prevalence of non­ calcified coronary plaques has 
yet to be established but does not seem to be related to 
ART54 and might be due to chronic inflammation and 
immune activation in treated HIV infection55,56.
Mechanisms of HIV- related atherogenesis
The pathogenesis of atherosclerosis in the setting of HIV 
infection is complex and poorly understood. Underlying 
mechanisms for HIV­ associated ASCVD include the 
effects of the HIV proteins on immune and vascular 
cells, the immunodeficiency caused by the HIV infec­
tion, co­ infection with CMV, microbial translocation 
from the gut, chronic inflammation and immune cell 
activation. These factors and their interrelationships are 
depicted in Fig. 2 and are summarized below.
HIV proteins. In individuals receiving ART, the HIV 
infection, although controlled, is not cured and there­
fore persists even when the virus is undetectable57, with 
low­ level transcription of HIV genes58. HIV­ encoded 
proteins, specifically transactivator of transcription 
(Tat) and negative factor (Nef), induce inflammation 
and endothelial dysfunction59. In addition, the HIV 
envelope protein gp120 has been shown to stimulate 
endothelin 1 production60. Therefore, by releasing low 
levels of certain damaging proteins, the HIV virus itself 
stimulates atherogenesis.
Table 2 | Effect of antiretroviral therapy on the risk of cardiovascular disease
Study (year) Study population arT Number of 
patients
Follow-up Cardiovascular  
end points
Findings refs
Bozzette et al. 
(2003)
Patients with HIV 
infection who 
received care at  
a VA centre
Combination therapy 
with PIs, nucleoside 
analogues and 
NNRTIs
36,766 8.5 years CVD and 
cerebrovascular 
disease
Use of ART was associated 
with a reduction in the risk 
of CVD
180
D:A:D study 
group (2003)
Patients with HIV 
infection
Combination 
regimen including  
a PI or an NNRTI
23,468 2.2 years MI Use of ART was associated 
with a 26% relative 
increase in rate of MI  
per year of exposure
181
SMART (2006) Patients with well- 
controlled HIV 
infection; cohort 
from 33 countries
Continuous ART 
versus episodic use 
of ART
5,472 16 months Opportunistic 
disease or death from 
any cause; major 
cardiovascular, renal 
or hepatic disease
Continuous ART reduced 
the risk of CVD compared 
with episodic use of ART
182
D:A:D study 
group (2007)
Patients with HIV 
infection
PIs or NNRTIs 23,437 5.2 years MI Exposure to PIs was 
associated with a higher 
rate of MI per year of 
exposure
25
D:A:D study 
group (2008)
Patients with HIV 
infection
NRTIs 33,347 7.2 years MI Use of abacavir or 
didanosine in the previous 
6 months was associated 
with increased risk of MI
28
Stein et al. 
(2015)
Patients with HIV 
infection without 
known CVD or 
diabetes mellitus 
who were initiating 
their first ART
NRTI, PI or integrase 
inhibitor
328 6.4 years Changes in carotid 
artery IMT
Atazanavir had a protective 
effect, with slower carotid 
IMT progression in the 
setting of high plasma 
bilirubin levels compared 
with other ART regimens
183
START (2015) Patients with HIV 
infection; cohort 
from 35 countries
Immediate initiation 
of ART versus 
deferred initiation 
of ART
4,299 6.4 years MI, stroke, coronary 
revascularization or 
CVD- related death
Early initiation of ART did 
not significantly reduce 
the incidence of the 
cardiovascular end point
184
Marconi et al. 
(2018)
Individuals with 
or without HIV 
infection and 
without known 
CVD
NRTI, PI or NNRTI 96,381 8.8 years CVD including acute 
MI, heart failure and 
stroke
Decreased risk of CVD in 
the setting of high plasma 
bilirubin levels irrespective 
of HIV infection status
120
Elion et al. 
(2018)
Patients with HIV 
infection
NRTI 8,265 12 years Type 1 and type 2 MI Use of abacavir in the past 
6 months was associated 
with increased risk of MI
31
D:A:D study 
group (2018)
Patients with HIV PIs 49,709 >15 years CVD Use of ritonavir- boosted 
darunavir but not ritonavir- 
boosted atazanavir was 
associated with increased 
risk of CVD
27
ART, antiretroviral therapy ; CVD, cardiovascular disease; IMT, intima–media thickness; MI, myocardial infarction; NNRTI, non- nucleoside reverse- transcriptase 
inhibitor; NRTI, nucleoside reverse- transcriptase inhibitor; PI, protease inhibitor ; VA , Veterans Affairs.
Nature reviews | Cardiology
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Immunodeficiency. CD4+ T cell depletion is the hallmark 
of HIV infection, and nadir CD4+ T cell count is a rough 
marker of the severity of immunodeficiency. Nadir CD4+ 
T cell count was first linked to features of atherosclero­
sis, such as increased carotid intima–media thickness61 
and increased arterial stiffness62. Soon thereafter, lower 
nadir CD4+ T cell counts were shown to be associated 
with incident MI in two cohort studies63,64. In another 
report in which cardiovascular events were adjudicated 
more stringently, type 1 MI (the atherothrombotic type) 
occurred more commonly in people either with lower 
CD4+ T cell counts or with detectable HIV RNA65. The 
CD4:CD8 ratio, a marker of immunosenescence, has been 
predictive of cardiovascular events in some66,67 but not 
other68 studies. Among individuals with HIV infection 
in New York City, USA, CVD mortality was highest 
among individuals with detectable viraemia (adjusted 
rate ratio (RR) 3.53, 95% CI 3.21–3.87), although even 
individuals with viral suppression had elevated CVD 
mortality (adjusted RR 1.53, 95% CI 1.41–1.66) com­
pared with the general population69. These findings 
indicate that markers of immune system damage and 
viral detectability are related to cardiovascular events 
in patients with HIV. Immune abnormalities persist in 
individuals with HIV infection even after successful 
treatment with ART. The mechanisms linking immune 
system damage in HIV infection to atherosclerosis have 
not been elucidated. Although non­ AIDS­related events, 
such as MI and stroke, are less common with com­
plete viral suppression, these events still occur at rates 
considerably higher than in an uninfected population.
CMV co- infection. Co­ infection with CMV might con­
tribute to HIV­ associated atherosclerosis. Compared 
with individuals without HIV infection, patients 
infected with HIV consistently have a higher propor­
tion of CMV­ specific CD8+ T cells, with the highest 
levels seen in patients with HIV suppression who are 
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and innate immunity
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Chronic inﬂammation
Dyslipidaemia
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Fig. 2 | Pathophysiology and management of HiV- associated atherosclerotic cardiovascular disease. Schematic 
representation of the effects of HIV infection (in red) and the available strategies (in green), as well as approaches under 
investigation (in purple), for reducing the risk of atherosclerotic cardiovascular disease (ASCVD) and chronic inflammation 
in this patient population. In the setting of HIV infection, the increased microbial translocation from the gut, the continued 
HIV viral replication and the HIV- induced immunodeficiency , along with traditional ASCVD risk factors, contribute to 
immune cell activation and chronic inflammation. HIV- specific interventions to reduce the risk of ASCVD include 
strategies targeted at co- infections (such as Cytomegalovirus (CMV) infection), use of newer antiretroviral therapies (ARTs) 
and intensification of ART. Strategies aimed at eradicating the HIV infection are under investigation. Treatments targeting 
traditional ASCVD risk factors, such as hypertension, diabetes mellitus, smoking and metabolic syndrome, are also critical 
for reducing the risk of ASCVD in patients with HIV infection. Use of anticoagulants, β- blockers, angiotensin- converting 
enzyme (ACE) inhibitors and LDL cholesterol (LDL- C)-lowering agents (such as statins and PCSK9 inhibitors) reduce the 
risk of ASCVD in patients with cardiovascular disease without HIV infection and might, therefore, be useful in reducing 
the risk of HIV- associated ASCVD. Finally , strategies to lower inflammation, such as canakinumab, which has been 
reported to reduce cardiovascular events significantly in a non- HIV patient population, might also reduce the risk of 
HIV-associated ASCVD.
Nadir CD4+ T cell count
The lowest CD4+ T cell count 
an individual has had, which 
serves as a marker for 
immunodeficiency.
Immunosenescence
Changes to the immune 
system that can be associated 
with age.
Viraemia
Presence of viral particles in 
the blood.
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receiving long­ term ART70. CMV­ specific responses 
seem to underlie immunosenescence or immunological 
ageing in HIV infection71. Co­ infection with CMV is 
strongly linked to HIV viral persistence and might also 
have a role in chronic immune activation and inflam­
mation by expansion of the HIV reservoir72. These 
CMV­ specific T cell responses also have been shown to 
correlate with markers of atherosclerosis, such as carotid 
intima–media thickness73–75 and coronary artery calcifi­
cation75. High CMV antibody titres in patients with HIV 
infection, and titres to other viruses such as herpes sim­
plex virus and varicella­ zoster virus, are associated with 
higher levels of biomarkers that accelerate inflamma­
tion and atherosclerosis74. Analogously, CMV also has 
an important role in the coronary atherosclerosis that 
develops in heart transplantation recipients76.
Gut microbial translocation. Impairment of the gut 
barrier is an early feature of HIV infection, leading to 
microbial translocation, a process whereby microbial 
products leak through the intestinal barrier and cause 
immune activation77. Plasma levels of soluble CD14 
(sCD14) and lipopolysaccharide are markers of micro­
bial translocation that independently predict HIV dis­
ease progression78 and mortality79 in individuals who are 
not receiving ART. Conflicting data exist as to whether 
these markers are predictive of adverse outcomes in 
ART­ treated individuals; however, gut damage and 
microbial translocation persist even when HIV infection 
is suppressed by ART77. Plasma levels of inflammatory 
markers, specifically IL­6 and tumour necrosis factor, 
have been reported to be higher in individuals with 
higher levels of markers of microbial translocation80. 
Therefore, microbial translocation is another mechanism 
that might contribute to the atherogenesis associated 
with HIV infection. However, interventions targeting 
this mechanism, including sevelamer81, rifaximin80, 
probiotic administration82 and mesalamine83, have not 
consistently lowered inflammatory markers or T cell 
activation. As these studies targeted a variety of patient 
populations (treated versus untreated HIV infection), 
evaluated different inflammatory markers and were gen­
erally short in duration, the definitive role of microbial 
translocation from the gut in HIV­ associated ASCVD 
remains unclear and requires additional investigation.
Chronic inflammation and immune cell activation. 
latent HiV infection, co­ infection with other viruses 
and microbial translocation all influence atherogene­
sis by increasing inflammation. HIV infection is asso­
ciated with high levels in plasma of inflammation and 
coagulation markers, such as CRP, IL­6 and d­ dimer, 
and these biomarkers strongly predict cardiovascular 
events and all­ cause mortality in individuals with HIV 
infection84–86. Arterial and lymph node inflammation 
as assessed by FDG­ PET and CT imaging are higher in 
patients with HIV infection than in individuals without 
HIV infection, and this increased inflammation cor­
relates with higher circulating levels of CRP, IL­6 and 
activated monocytes87,88.
Inflammation offers a potential therapeutic target 
for the reduction of cardiovascular events in individuals 
with or without HIV infection; some postulated thera­
pies to lower inflammation in HIV infection are depicted 
in Fig. 2. In patients with atherosclerosis without HIV 
infection, the beneficial effect of statin therapy is thought 
to be due not only to a reduction in plasma LDL­ C levels 
but also to a reduction in inflammation89. In the presence 
of HIV infection, the anti­ inflammatory effects of statins 
on markers of inflammation seem to be attenuated90,91. 
Changing protease­ inhibitor­based regimens to integrase 
inhibitors does not consistently reduce inflammatory 
parameters92, and intensification of ART does not have a 
major salutary effect on inflammatory markers93,94. Short 
studies of aspirin therapy also had no effect on inflam­
matory markers in HIV infection95. Taken together, these 
findings suggest that strategies in addition to ART and 
targeting of traditional CVD risk factors are needed to 
reduce inflammation with the aim of lowering the risk 
of ASCVD in the setting of HIV infection.
Although T cell activation is a strong predictor of 
HIV disease progression96, inflammatory and coagula­
tion biomarkers, including IL­6, soluble tumour necrosis 
factor receptor type I (sTNFRI), tumour necrosis factor 
receptor type II (TNFRII), kynurenine:tryptophan ratio 
and d­ dimer, but not T cell activation, were predictive 
of non­ AIDS events including CVD97. Some studies 
have implicated T cell activation in HIV infection with 
other indices of atherosclerosis, including carotid artery 
intima–media thickness98 and arterial stiffness99. The 
effect of T cell activation in HIV­ associated vascular 
disease seems to be at the microvascular level, which 
serves as the stimulus for flow­ mediated vasodilata­
tion (a marker of macrovascular disease)100. Therefore, 
T cell activation in HIV infection might worsen micro­
vascular disease, leading to endothelial dysfunction and 
subsequent cardiovascular events.
Canakinumab, a monoclonal antibody targeting 
IL­1β, was evaluated in a randomized, placebo­controlled 
trial involving 10,061 patients with previous MI and a 
high­ sensitivity CRP (hsCRP) level of ≥2 mg/l (reF.101). 
The three doses of canakinumab that were tested all 
reduced hsCRP levels, ranging from 26% reduction with 
the 50 mg dose to 41% with the 300 mg dose, but did 
not affect LDL­ C levels. At the intermediate and higher 
doses, canakinumab reduced the primary composite end 
point of CVD­ related death, MI and stroke. Patients who 
had a hsCRP reduction to <2 mg/l had significant reduc­
tions in cardiovascular events, CVD­ related mortality 
and all­ cause mortality, whereas no significant reduc­
tion in these outcomes was observed in patients who did 
not achieve the hsCRP reduction to this level102. Similar 
findings were reported for individuals who achieved 
on­ treatment IL­6 levels below the study median value 
of 1.65 ng/l — namely, a 32% reduction in major adverse 
cardiovascular events, a 52% reduction in CVD­ related 
mortality and a 48% reduction in all­ cause mortality103. 
Canakinumab therapy was associated with a higher 
incidence of fatal infection than placebo101.
Would canakinumab reduce cardiovascular events 
in individuals infected with HIV? In a small study in 
patients with HIV infection, our group has shown that 
canakinumab therapy significantly reduced plasma IL­6 
and hsCRP levels, with no effect on CD4, CD8 or RNA 
Latent HIV infection
a dormant or non- replicative 
HiV infection within a cell; in 
this state, the virus is not 
actively infecting other cells 
and individuals do not usually 
have noticeable symptoms.
Nature reviews | Cardiology
R e v i e w s
viral levels104. Inflammation in the bone marrow and 
arterial inflammation were reduced after a single dose 
of canakinumab. By contrast, in another study published 
in 2018, low­ dose methotrexate significantly lowered the 
CD8+ T cell count but had no effect on inflammatory 
markers or endothelial function105. However, low­ dose 
methotrexate did favourably affect specialized ultra­
sonography indices in the brachial artery106. These 
preliminary studies with inflammatory biomarkers as 
surrogate end points will hopefully lead to clinical trials 
on anti­ inflammatory treatments with cardiovascular 
events as end points in the population living with HIV.
As previously noted, markers of inflammation and 
coagulation predict cardiovascular events in individu­
als with HIV infection84–86. A summary of markers stud­
ied in different cohorts of patients with HIV infection 
and the association with clinical outcomes is shown in 
Table 3. The strong relationship between inflammatory 
and coagulation markers is striking and apparent even in 
the setting of diverse HIV­ infected populations includ­
ing men, women and older and younger individuals. 
In combined data from three large cohorts of patients 
with HIV infection, IL­6 and d­ dimer levels in plasma 
were independently associated with the risk of seri­
ous non­ AIDS events or death, with an estimated 37% 
reduction in non­ AIDS events or death resulting from a 
25% decrease in IL­6 or d­ dimer levels107. Aside from 
prediction of clinical events, plasma levels of soluble 
CD163 (sCD163), a marker of macrophage activity, was 
associated with higher levels of arterial inflammation in 
HIV infection87.
In the general population, the immune system has 
been implicated in atherosclerosis as well as in con­
duction system disorders, myocarditis and heart fail­
ure with preserved ejection fraction108. In particular, 
the role of haematopoietic stem cells, inflammation 
and macrophages has been associated with these con­
ditions; therefore, it is plausible that immune system 
abnormalities that are present in HIV infection underlie 
HIV­ associated CVDs. HIV infects CD4+ T cells, most 
of which reside in secondary lymphoid tissues, such as 
the lymph nodes109. Myeloid cells, which include mono­
cytes, dendritic cells and macrophages, have a crucial 
role in HIV disease pathogenesis110,111. Macrophage 
infiltration has been observed in the hearts of monkeys 
infected with simian immunodeficiency virus (SIV), and 
macrophage infiltration correlated with fibrosis and car­
diac pathology112. Anti­ inflammatory therapy with 
natalizumab (a monoclonal antibody against the cell 
adhesion molecule α4 integrin) reduced the number of 
macrophages in cardiac tissue as well as cardiac patho­
logy in this animal model113. Monocyte and macrophage 
markers, including sCD163 and sCD14 levels in plasma 
and CD14+CD16+ cell counts, have been linked to 
subclinical atherosclerosis in HIV infection in a variety 
of studies113.
A 2018 study showed that biomarkers in HIV 
infection can be grouped into clusters, with each clus­
ter related to a cardiac phenotype114. For example, the 
inflammatory phenotype is characterized by higher 
levels of CRP, IL­6 and d­ dimer, whereas the cardiac 
phenotype comprised a clustering of higher levels 
of protein ST2 (also known as IL­1 receptor­ like 1), 
N­terminal pro­ B­type natriuretic peptide and growth/
differentiation factor 15. Diastolic dysfunction was 
common in the inflammatory group of biomarkers, 
and pulmonary hypertension was more common in 
the cardiac group of markers. Both phenotypes were 
associated with a threefold increase in mortality over a 
6.9­year follow­ up after adjustment for other prognostic 
variables. Biomarker clusters in patients with HIV might 
be helpful for selecting patients for appropriate therapy 
to reduce cardiovascular events.
ART- related mechanisms. The most obvious mecha­
nism by which ART increases the risk of CVD is through 
worsening of blood lipid levels. The increase in LDL­C 
levels with protease inhibitors seems to result from 
Table 3 | associations of inflammatory and coagulation biomarkers with mortality in HiV infection
Study (year) Study population Number of 
patients
Follow- up Findings refs
SMART (2008) Patients with well- controlled HIV 
infection; cohort from 33 countries
5,472 3,700 person- years • IL-6 and d- dimer levels in plasma were strongly 
associated with all- cause mortality
• IL-6, hsCRP and d- dimer levels in plasma were 
associated with increased risk of CVD
84,185
FRAM (2010) Patients with HIV infection 922 5 years Fibrinogen and CRP levels were strong and 
independent predictors of mortality
186
ALLRT (2014) Patients with HIV infection who had 
achieved virological suppression 
within 1 year after ART initiation
143 48–64 weeks after 
ART initiation
High IL-6, sTNFRI, sTNFRII and d- dimer levels in 
plasma and KT ratio at 1 year were associated 
with increased risk of non- AIDS events
97
VACS (2016) Patients with HIV infection and 
individuals without infection
2,350 6.9 years HIV infection was associated with elevated IL-6, 
sCD14 and d- dimer levels in plasma, which are 
associated with mortality
187
MACS (2016) Patients with well- controlled HIV 
infection
670 Up to 18 years IL-6 and sCD14 levels in plasma were predictive 
of mortality
188
START (2017) Patients with HIV infection; cohort 
from 35 countries
4,299 3.2 years Baseline IL-6 and d- dimer levels in plasma  
were associated with the risk of AIDS, serious 
non- AIDS events or death
189
ART, antiretroviral therapy ; CRP, C- reactive protein; CVD, cardiovascular disease; hsCRP, high- sensitivity C- reactive protein; KT, kynurenine:tryptophan; sCD14; 
soluble CD14; sTNFRI, soluble tumour necrosis factor receptor type I; sTNFRII, soluble tumour necrosis factor receptor type II.
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increased cholesterol absorption rather than increased 
synthesis115. Whereas some ARTs increase LDL­ C levels, 
other ARTs, particularly older protease inhibitors, 
induce hypertriglyceridaemia, with ritonavir being the 
worst culprit116. Interestingly, in the large D:A:D study117, 
even after adjustment for blood lipid levels, cumulative 
exposure to the NRTIs abacavir or didanosine or to the 
protease inhibitors lopinavir–ritonavir or indinavir was 
associated with an increased risk of MI. Newer protease 
inhibitors, as well as the integrase inhibitor raltegravir 
and the virus­ entry inhibitor maraviroc, have favourable 
effects on lipid levels, particularly compared with older 
types of ARTs118.
ART might also increase the risk of ASCVD through 
other mechanisms. Insulin resistance, lipodystrophy 
and other patterns of fat distribution can contribute to 
atherogenesis. The NRTI abacavir has been linked to an 
increased risk of MI in some28–31 but not all studies33. 
This increase in risk has been attributed to increased 
platelet reactivity32 and to endothelial dysfunction119. 
In the D:A:D study26, a difference in the risk of MI was 
noted between the widely used protease inhibitors, 
atazanavir and darunavir, with atazanavir being associ­
ated with a lower risk of MI than darunavir. This reduced 
risk of MI has been suggested to reflect a protective effect 
of atazanavir given the bilirubin­ raising activity of the 
drug120. Overall, we emphasize that current ART regi­
mens are associated with a much lower risk of CVD than 
older ART regimens.
Understanding the role of inflammation and inflam­
matory biomarkers in the general population with 
coronary heart disease has taken several decades to 
establish121,122, including ascertaining which markers 
have prognostic importance as opposed to being on the 
causal pathway. Although research on inflammatory bio­
markers of the risk of CVD in HIV infection has been 
performed, much additional work is needed to iden­
tify the best biomarker in the setting of HIV infection 
along with the effect of HIV­ related factors (including 
immune dysfunction) and traditional CVD risk factors. 
Identifying how ART, treatments for CVD and potential 
anti­ inflammatory strategies change these inflammatory 
pathways and biomarkers will also be critical to advance 
the field. Of note, risk calculators used in the general 
population are inaccurate in patients infected with HIV 
and systematically underestimate risk123. Using non­ 
biased methods, such as proteomics, which have been 
used in the general population, might be helpful to 
develop HIV­ specific risk scores124.
Management of CVD risk in HIV infection
Dyslipidaemia. The onset of HIV infection is asso­
ciated with a decline in total cholesterol, LDL­ C and 
HDL­ C levels125. In a study comparing patients with 
HIV infection with matched uninfected controls, 
the group with HIV infection had lower HDL­ C and 
LDL­ C levels and higher triglyceride, CRP and IL­6 
levels126. Because starting ART is now recommended 
at the time of initial HIV diagnosis, the lipid pattern of 
untreated HIV infection is seen only among individu­
als who live in resource­ limited settings and, therefore, 
do not have access to ART. Of note, in a meta­ analysis 
of 80 studies, the greatest risk of CVD in HIV infec­
tion was found to be in sub­ Saharan Africa and the 
Asia Pacific regions18.
The effect of ART on blood lipid levels varies across 
the classes of ART drugs and between drugs within the 
same class, as broadly summarized in Table 4 (of note, 
this summary is not meant to be comprehensive). The 
effects of individual drugs are difficult to ascertain 
because HIV treatment typically requires three or four 
drugs. Generally, protease inhibitors, NRTIs and non­ 
NRTIs (NNRTIs) all increase triglyceride levels and 
can increase LDL­ C levels. LDL­ C and triglyceride 
levels increase more with dual than with single protease 
inhibitor therapy.
Important differences have been described between 
protease inhibitors; in a report from the D:A:D study116, 
ritonavir and ritonavir­ containing regimens increased 
triglyceride and LDL­ C levels more, saquinavir caused 
less abnormally low HDL­ C levels and nelfinavir was 
associated with fewer patients presenting with a high 
total cholesterol:HDL­ C ratio compared with other pro­
tease inhibitors. In another study, LDL­ C level increased 
by a mean of 2.0 mmol/l with initiation of ritonavir, 
0.8 mmol/l with indinavir and 1.2 mmol/l with nelfina­
vir127. Ritonavir, but not the other two protease inhibitors, 
was associated with very elevated plasma triglyceride 
levels. Ritonavir can sometimes cause extreme hypertri­
glyceridaemia, with levels >10 mmol/l, and result in pan­
creatitis. Lower doses of ritonavir than those used in the 
study are now usually used, but hypertriglyceridaemia is 
also seen with combinations of ritonavir–saquinavir and 
ritonavir–lopinavir. Compared with these older protease 
Table 4 | Effect of antiretroviral therapies on blood lipid levels190
Class drug Effect on blood lipids refs
Protease 
inhibitors
Atazanavir Increases HDL- C and decreases LDL- C 
levels
191
Darunavir Increases HDL- C levels 191
Fosamprenavir Hypertriglyceridaemia 192
Ritonavira Increases HDL- C levels 191
Saquinavir Neutral 192
Tipranavir Dyslipidaemia 192
NRTIs Abacavir Increases total cholesterol, LDL- C and 
HDL-C levels
193
Lamivudine Increases total cholesterol, LDL- C and 
HDL-C levels
193
Tenofovir fumarate 
disoproxil
Lowers LDL levels 194
Zidovudine Hypertriglyceridaemia 194
NNRTIs Efavirenz Increases total cholesterol, LDL- C, HDL- C 
and triglyceride levels
193
Nevirapine Neutral or decreases lipid levels 195
Rilpivirine Neutral 193
Integrase 
inhibitors
Dolutegravir Neutral 133
Raltegravir Increases HDL levels 191
HDL- C, HDL cholesterol; LDL- C, LDL cholesterol; NNRTI, non- nucleoside reverse- transcriptase 
inhibitor ; NRTI, nucleoside reverse- transcriptase inhibitor. aAlthough ritonavir is a protease 
inhibitor, this drug is generally used as a pharmacokinetic enhancer.
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inhibitors, use of atazanavir and darunavir is associated 
with more favourable lipid profiles128.
NNRTIs also increase LDL­ C levels but do not 
decrease HDL­ C levels13. Among NNRTIs, efavirenz 
was associated with slightly more patients developing 
hypercholesterolaemia and hypertriglyceridaemia than 
nevirapine116. Efavirenz has been associated with greater 
increases in total cholesterol and LDL­ C but not total 
cholesterol:HDL­ C ratio compared with the atazanavir–
ritonavir combination129. Compared with the NNRTI 
rilpivirine, efavirenz is associated with higher total cho­
lesterol, HDL­ C, LDL­ C and triglyceride levels130. The 
newer formulation of the NRTI tenofovir (tenofovir 
alafenamide) is associated with higher levels of both 
LDL­C and HDL­C, but similar total cholesterol:HDL­C 
ratio, compared with the older formulation (tenofovir 
disoproxil fumarate), which has a lipid­ lowering effect131.
Newer ARTs, such as the integrase inhibitors, the 
CC­ chemokine receptor 5 (CCR5)­co­ receptor antago­
nist maraviroc and second­ generation protease inhib­
itors, such as atazanavir, favourably affect lipid levels, 
especially compared with older ARTs, and are associ­
ated with improvements in surrogate markers of athero­
sclerosis, such as flow­ mediated vasodilatation and 
carotid intima–media thickness132. The integrase inhibi­
tors dolutegravir and raltegravir seem to affect blood 
lipids in a similar way133.
Across various studies, the prevalence of hyper­
lipidaemia among people living with HIV ranges from 
28% to 80%, with hypertriglyceridaemia being the most 
common abnormality134. Intrinsic differences in study 
populations and the evolution of ART over time are 
probable explanations for this broad range. Most of 
the studies described here were of fairly short duration 
and were usually done in North American or European 
popu lations. However, ART is now initiated most often 
in people living in sub­ Saharan Africa, where data 
defining the metabolic effects of treatment are scarce. 
In a 2018 meta­ analysis of 14 trials and including a 
total of 21,023 individuals from this region, ART was 
associated with an increased risk of hypertriglyceri­
daemia (RR 2.05, 95% CI 1.51–2.77); however, no con­
sistent associations were observed between ART and 
raised blood pressure, blood glucose levels, glycated 
haemoglobin (HbA1c) levels or other blood lipids135.
In one study, hypertriglyceridaemia in patients with 
HIV infection was related to their higher intake of total 
fat, saturated fat and cholesterol compared with individ­
uals without HIV infection136. Saturated fat intake was 
strongly correlated with triglyceride levels, suggesting 
that dietary modification to decrease saturated fat intake 
might be a logical approach to control high triglyceride 
levels in patients with HIV infection.
Until recently, guidelines for cholesterol management 
have not specifically addressed individuals living with 
HIV. The 2016 ESC/European Atherosclerosis Society 
(EAS) guidelines devote a short section to individuals 
with HIV infection and recommend dietary changes 
and exercise, as well as switching, when feasible, to a 
more ‘lipid­ friendly’ ART137. The guidelines also state 
that statin therapy should be considered to achieve the 
target LDL­ C level of 2.8 mmol/l, the same target that is 
recommended for other patients at high risk of CVD. 
The US National Lipid Association recommended con­
sidering HIV infection as an independent risk factor 
for selecting drug therapy to lower LDL­ C levels138. The 
2018 ACC/AHA guidelines state that HIV infection 
can be considered a CVD risk enhancer, which would 
favour starting moderate­ intensity or high­ intensity 
statin therapy139.
Many clinical trials have documented that LDL­ C 
lowering, usually with statin therapy, reduces the risk 
of cardiovascular events across a broad spectrum of 
patients without HIV infection. Similar data are not 
yet available for people with HIV infection; however, 
the REPRIEVE trial140, launched in 2015, will address 
this issue. As previously noted, in a small, randomized 
trial in patients with HIV infection, atorvastatin signif­
icantly reduced non­ calcified coronary plaque volume 
compared with placebo during a follow­ up of 1 year53.
Drug–drug interactions are important considera­
tions when initiating lipid­ lowering drugs in patients 
infected with HIV. A systematic review of 18 statin trials 
in patients with HIV infection receiving ART demon­
strated that statin therapy can be administered safely in 
this patient population141. Use of lovastatin and simvas­
tatin with protease inhibitors is contraindicated owing 
to the risk of rhabdomyolysis from high statin levels in 
blood134. Use of ritonavir with protease inhibitors seems 
to increase the area under the curve for atorvastatin as 
well; therefore, guidelines from the Infectious Diseases 
Society of America suggest starting at lower doses of 
atorvastatin in individuals receiving protease inhibitor­ 
based regimens142. Rosuvastatin levels in blood increase 
when used with atazanavir–ritonavir and lopinavir–
ritonavir; therefore, the dose of rosuvastatin should be 
limited to 10 mg when used in combination with these 
drugs143. Pravastatin and fluvastatin are safer to use in 
combination with ART but do not lower LDL­ C levels 
as much as atorvastatin or rosuvastatin. Pravastatin and 
fluvastatin were widely used after the introduction of 
ART but are less popular now owing to the growing 
realization, reflected in contemporary guidelines, that 
greater degrees of LDL­ C lowering yield greater reduc­
tions in the risk of cardiovascular events144. Pitavastatin 
might be a good compromise for some people with HIV 
infection; this drug is metabolized via glucuronidation, 
thereby avoiding drug–drug interactions145, and, at 
higher doses, pitavastatin shows moderate LDL­ C low­
ering. In one randomized study in patients with HIV 
infection, pitavastatin (4 mg per day) reduced LDL­ C 
level by 31% and pravastatin (40 mg per day) reduced 
LDL­ C level by 21% from baseline levels, with similarly 
low rates of adverse effects for both statin treatments146. 
According to a 2018 study, as many as 50% of individuals 
with HIV infection were eligible for statin therapy on the 
basis of at least one US guideline, but not all the eligible 
patients were prescribed statins147. Even when individu­
als are receiving statin therapy, those with HIV infection 
might not achieve as much lipid lowering as individuals 
without HIV infection; namely, a meta­ analysis of stud­
ies in people living with HIV infection demonstrated 
that only a low percentage achieved the expected reduc­
tion in LDL­ C level after initiation of statin therapy148. 
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From 2007 to 2014, the percentage of individuals with 
HIV infection taking a contraindicated (owing to their 
ART) statin decreased; however, this decreasing trend 
was attenuated in 2015 owing to an increase in the use 
of the ART cobicistat149.
In individuals with HIV infection who do not toler­
ate statins, ezetimibe is a safe option, albeit with limited 
LDL­ C­lowering efficacy150. Ezetimibe can be used in 
addition to a maximally tolerated statin dose for indi­
viduals with HIV infection who are at a very high risk 
of CVD and do not achieve satisfactory LDL­ C lowering 
with statin therapy alone. Use of bile acid sequestrants is 
not appropriate in the setting of HIV infection because 
these agents increase plasma triglyceride levels and 
their effect on the absorption of ARTs is unknown151. 
Individuals with HIV infection often have a high pill 
burden, and an add­ on therapy might present additional 
challenges.
Switching ART to drugs that do not adversely affect 
blood lipids is worthwhile as long as viral suppression is 
maintained. Switching from older protease inhibitors to 
integrase inhibitors improves blood lipid levels, but at 
the cost of an increased rate of virological failure152 and, 
therefore, is not recommended for individuals with a 
history of virological failure. In another study of patients 
with HIV infection and high risk of CVD, continuing 
on a ritonavir­ boosted protease inhibitor regimen or 
switching to dolutegravir (an integrase inhibitor) was 
associated with similar rates of virological failure after 
48 weeks; however, total cholesterol, LDL­ C and trigly­
ceride levels all improved (P < 0.0001) in the dolutegravir 
group153. For those not already taking a statin, adding 
statin therapy is probably preferable to switching the 
type of ART; in one study, adding rosuvastatin (10 mg 
per day) was better tolerated and yielded better blood 
lipid results than switching154.
The common problem of hypertriglyceridaemia in 
patients with HIV infection should first be addressed 
by reducing intake of carbohydrates, including alco­
hol. When plasma triglyceride levels exceed 10 mmol/l, 
pancreatitis is a serious risk and immediate treatment is 
required, but lower levels of hypertriglyceridaemia are 
not benign because they probably increase the risk of 
CVD. Fibrates are widely used to lower triglyceride levels 
in people without HIV infection but have a drug–drug 
interaction with statins and some types of ART. A change 
in ART to drugs that induce less hypertriglyceridaemia 
is often the best approach.
Diabetes and the metabolic syndrome. Whether HIV 
infection itself is associated with an increased risk of 
diabetes or whether the increased risk is related only 
to specific ART drugs has been controversial. Protease 
inhibitors and the thymidine analogue stavudine can 
cause insulin resistance118; however, these drugs are now 
not often used owing to their toxicity. In a large cohort 
study from Denmark, the risk of diabetes among patients 
with HIV infection was nearly triple that of the general 
population in 1996–1999, but this excess was absent in 
1999–2010 (reF.155). Conversely, a cross­ sectional study 
from sub­ Saharan Africa published in 2018 reported a 
higher prevalence of diabetes and a HbA1c level of ≥6% 
in people living with HIV infection compared with 
uninfected controls156.
Lipodystrophy is a syndrome that results in central 
adiposity from fat accumulation in the dorsocervical 
region, increased or preserved visceral fat and periph­
eral fat loss157 and can be divided into lipoatrophy and 
lipohypertrophy158. Excess visceral adiposity is associ­
ated with insulin resistance among individuals with 
or without HIV infection159. Lipodystrophy develops 
in 20–35% of patients taking older protease inhibitors 
or the NRTIs didanosine or stavudine160,161; however, 
newer protease inhibitors, such as atazanavir, do not 
seem to cause lipodystrophy37,160,161. Lipodystrophy is 
often associated with insulin resistance, impaired glu­
cose tolerance, hypertriglyceridaemia, low HDL­ C levels 
and hypertension.
Reported rates of metabolic syndrome in people with 
HIV infection range from 8.5% to 52%, with rates at the 
lower end of this range seen in multicentre studies in 
which patients had less exposure to ART and rates at 
the higher end found in Latin American countries118. 
Metabolic syndrome usually develops in the first 3 years 
after starting an ART regimen that includes lopinavir–
ritonavir or stavudine. According to most studies, meta­
bolic syndrome is a predictor of cardiovascular events 
and death in people living with HIV infection, as in 
individuals without the infection118. Among the general 
population, development of chronic kidney disease is 
increased in the setting of metabolic syndrome162, and 
blood pressure is a component of metabolic syndrome 
using Adult Treatment Panel III (ATP III) criteria163.
The prevalence of hypertension and chronic kidney 
disease does not seem to be higher than normal in people 
with HIV infection, with the exception of a higher inci­
dence of chronic kidney disease among patients exposed 
to some ART regimens164. Nevertheless, hypertension 
and prehypertension have been shown to be risk factors 
for cardiovascular events in people with HIV infection, 
just as in individuals without the infection165. Similarly, 
chronic kidney disease, defined as either albuminuria or 
a decreased glomerular filtration rate, is associated with 
an increased risk of cardiovascular events in patients 
with HIV infection166. Among 35,357 patients with HIV 
in the D:A:D cohort, lower glomerular filtration rate was 
strongly associated with a higher risk of CVD167.
Smoking. The prevalence of cigarette smoking among 
individuals with HIV infection is extremely high. In a 
large cohort study from Denmark, nearly half of people 
with HIV infection smoked compared with one­ fifth 
of people without HIV infection168. All­ cause mortality 
was much higher among smokers than nonsmokers with 
HIV infection. For example, an individual aged 35 years 
and living with HIV infection had a median life expec­
tancy of 62.6 years (95% CI 59.9–64.6 years) if a smoker 
and 78.4 years (95% CI 70.8–84.0 years) if a nonsmoker. 
More life­ years were lost owing to smoking than to HIV 
(12.3 versus 5.1). The population­ attributable risk of 
death due to smoking was 61.5% in individuals with HIV 
and 34.2% among people without the infection. These 
statistics emphasize the importance of stopping smoking 
for patients with HIV infection.
Virological failure
refers to the failure of the HiV 
treatment to supress the virus 
completely; the virus is 
detectable in the blood 
(>200 copies per ml). This 
failure can occur as a result of 
drug resistance, drug toxicity 
or noncompliance with 
antiretroviral therapy.
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Smoking cessation programmes are reported to have 
the same modest success rates in people with HIV infec­
tion as has been reported in individuals without HIV 
infection. In a meta­ analysis of eight trials including 
1,822 patients with HIV who were smokers, behavioural 
interventions increased abstinence rates by half (relative 
risk 1.51, 95% CI 1.17–1.95)169, and a meta­ analysis of 
smoking cessation interventions demonstrated that 
long­ term outcomes were similar among individuals 
with or without HIV infection170. In one study, physi­
cians trained to provide smoking cessation counselling 
and treatment for individuals living with HIV infection 
succeeded in significantly increasing smoking cessation 
rates and decreasing relapse rates171. Potential drug–
drug interactions between ART and drugs for smoking 
cessation have not been well studied. Studies of varen­
icline, bupropion and nicotine­ replacement therapy in 
people with HIV infection have generally been small, 
short and uncontrolled but have shown similar safety 
and success rates to reports in individuals without 
HIV infection172,173.
The effect of smoking cessation on the rates of sub­
sequent cardiovascular events was reported for a large 
cohort in the D:A:D study174. At baseline, 11,951 par­
ticipants (44%) were currently smoking and during 
the follow­ up period, 69% of them stopped smoking 
at least once. The incidence RR for MI compared with 
never smokers decreased from 3.73 (95% CI 2.46–5.64) 
within the first year of smoking cessation to 3.00 
(95% CI 1.84–4.88) within 1–2 years, to 2.62 (95% CI 
1.42–4.83) at 2–3 years and to 2.07 (95% CI 1.19–3.63) 
after >3 years. Similar trends were seen for total coronary 
events and total cardiovascular events. Although cardio­
vascular event rates were still approximately double 
the rate in never smokers after 3 years, the rates were 
much lower than the rates in individuals who continued 
smoking, making smoking cessation a very desirable 
therapeutic goal.
Conclusions
In summary, atherosclerosis in the setting of HIV infec­
tion continues to be an important health concern that 
has implications on mortality, particularly in the future 
as this patient population continues to age. In the 20 years 
since the initial descriptions of MI were reported in 
patients with HIV infection175, ART has transformed 
HIV infection into a chronic disease condition, and pro­
gress has been made in determining the contribution of 
ART, chronic inflammation and immune activation as 
well as traditional CVD risk factors to this disease pro­
cess. However, much work remains to elucidate further 
the underlying mechanisms for HIV­ associated ASCVD 
as well as therapeutic strategies to lower the risk of CVD 
and treat CVD in patients with HIV infection, which will 
include implementation studies to improve outcomes and 
CVD management for people living with HIV infection.
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